The European Organisation for the Research and Treatment of Cancer (EORTC) supports the European Commissions initiative to simplify the EU rules for medical devices and to strengthen the competitiveness of the European medical device sector.
EORTC
NGO · Belgium
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Track EORTC in PolicySpeak: request access →
Work at EORTC? so we know who speaks for it.
Their record over time
EORTC filed 2 positions between 6 Oct 2025 and 2 Apr 2026, across 2 of the 326 legislative files tracked here, attaching a full position paper 1 time.
What they argued
The European Organisation for Research and Treatment of Cancer (EORTC) welcomes the Biotech Act as an initiative to support clinical research by improving the European legal framework. The Acts preamble explicitly outlines a commitment to supporting clinical trial sponsors, and particularly non-commercial sponsors that conduct the majority of minimal- and low-intervention clinical trials in the Union.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
- IDEE ECONOMICHE www.idee-economiche.it · 2 files in common
- Wirtschaftskammer Österreich · 2 files in common
- BEUC - The European Consumer Organisation · 2 files in common
- MedTech Europe · 2 files in common
- EFPIA · 2 files in common
Showing 5 of 44.
Is this your organization?
Everything on this page comes from EORTC’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.